Using xanthohumol to reduce symptoms of viral infections
Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans
This study is testing if taking xanthohumol daily can help people feel better and recover faster from viral infections compared to a placebo.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University of Vienna Academic / other |
| Locations | 1 site (Vienna) |
| Trial ID | NCT06286657 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate whether regular oral supplementation of xanthohumol can lessen the severity and duration of symptoms associated with viral infections. Participants will be enrolled in a placebo-controlled trial where they will receive either xanthohumol or a placebo twice daily for 90 days. Blood samples will be collected at the start of the study, and again at 45 and 90 days, to monitor any changes. If participants develop a respiratory infection during the study, they will be asked to perform a self-test to assess their condition.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults with a BMI between 18 and 28 kg/m².
Not a fit: Patients with food intolerances, chronic inflammatory diseases, or recent viral infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new dietary supplement option for patients to manage viral infection symptoms more effectively.
How similar studies have performed: While the specific use of xanthohumol for viral infections is novel, similar studies on dietary supplements for symptom management have shown varying degrees of success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * healthy * BMI \>18 kg/m² or \< 28kg/m² Exclusion Criteria: * food intolerances * food allergies * chronic inflammatory diseases * metabolic diseases * viral or bacterial infections within the last 3 weeks of inclusion * intake of immunosuppressive medication * severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months * influenza infection in the "current" flu season
Where this trial is running
Vienna
- University of Vienna — Vienna, Austria (Recruiting)
Study contacts
- Study coordinator: Ina Bergheim, Prof. Dr.
- Email: ina.bergheim@univie.ac.at
- Phone: +43-1-4277-54981
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.